Abstract
The onset and development of multiple myeloma (MM) are closely related to immunodeficiency of the host. Traditional chemotherapy eradicates MM cells directly through inducing cell death, resulting in many side effects and poor quality of life. However, MM remains incurable and will eventually become resistant to chemotherapy, and progression or relapse is inevitable. The immunotherapy represents a novel therapeutic approach with few side effects and good targeting capability. This article reviews literatures on clinical data evaluating 4 major immunotherapeutic approaches for MM, including cellular immunotherapy, humoral immunotherapy, radioimmunotherapy and immunomodulation. Key words: Multiple myeloma; Immunity, cellular; Immunity, humoral; Antibodies, monoclonal; Radioimmunotherapy; Immunomodulation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
